Close Menu

Bring on the Bull

Premium

Welcome back to what I’ve come to think of as the “bad news page.” Like you, I’ve had about enough of being inundated with news of the sagging financial state of the genomics industry, and watching our GTI sink lower and lower.

Sure, we’re in one of the worst bear markets in memory. But historically, bear markets happen far less frequently than bull markets, and are almost always followed by bulls much greater in growth than the bear was in loss.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.